Overview Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder Status: Terminated Trial end date: 2008-12-01 Target enrollment: Participant gender: Summary The primary objectives of this placebo-controlled trial are to evaluate effectiveness and safety of DOV 21,947 at two oral dose levels. Phase: Phase 2 Details Lead Sponsor: DOV Pharmaceutical, Inc.